Xiaobo Chen

Xiaobo Chen

Auto-generated profile, based on publicly available information

Xiaobo Chen

Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China (X.C.).

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Radiology
Verified
Journal Article
Closed access
ZSZhenwei Shi
Zhenwei Shi
XHXiaomei Huang
Xiaomei Huang
ZCZiliang Cheng
Ziliang Cheng
ZXZeyan Xu
Zeyan Xu
HLHuan Lin
Huan Lin
ZLZaiyi Liu
Zaiyi Liu
Background Breast cancer is highly heterogeneous, resulting in different treatment responses to neoadjuvant chemotherapy (NAC) among patients. A noninvasive quantitative measure of intratumoral heterogeneity (ITH) may be valuable for predicting treatment response. Purpose To develop a quantitative measure of ITH on pretreatment MRI scans and test its performance for predicting pathologic complete response (pCR) after NAC in patients with breast cancer. Materials and Methods Pretreatment MRI scans were retrospectively acquired in patients with breast cancer who received NAC followed by surgery at multiple centers from January 2000 to September 2020. Conventional radiomics (hereafter, C-radiomics) and intratumoral ecological diversity features were extracted from the MRI scans, and output probabilities of imaging-based decision tree models were used to generate a C-radiomics score and ITH index. Multivariable logistic regression analysis was used to identify variables associated with pCR, and significant variables, including clinicopathologic variables, C-radiomics score, and ITH index, were combined into a predictive model for which performance was assessed using the area under the receiver operating characteristic curve (AUC). Results The training data set was comprised of 335 patients (median age, 48 years [IQR, 42-54 years]) from centers A and B, and 590, 280, and 384 patients (median age, 48 years [IQR, 41-55 years]) were included in the three external test data sets. Molecular subtype (odds ratio [OR] range, 4.76-8.39 [95% CI: 1.79, 24.21]; all P < .01), ITH index (OR, 30.05 [95% CI: 8.43, 122.64]; P < .001), and C-radiomics score (OR, 29.90 [95% CI: 12.04, 81.70]; P < .001) were independently associated with the odds of achieving pCR. The combined model showed good performance for predicting pCR to NAC in the training data set (AUC, 0.90) and external test data sets (AUC range, 0.83-0.87). Conclusion A model that combined an index created from pretreatment MRI-based imaging features quantitating ITH, C-radiomics score, and clinicopathologic variables showed good performance for predicting pCR to NAC in patients with breast cancer. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Rauch in this issue.


23 February 2016 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
XCXiaobo Chen
Xiaobo Chen
Zhaoliang SuZhaoliang Su
Zhaoliang Su
SWShengjun Wang
Shengjun Wang
HXHuaxi Xu
Huaxi Xu
BACKGROUND: ADP-ribosylation factor (ARF)-like 4c (Arl4c) has been reported to promote tumorigenesis in colorectal and lung cancers and may represent a novel therapeutic target. The aim of this study was to investigate the expression of ADP-ribosylat

4 June 2025 in EBioMedicine
Verified
Journal Article
Open access
CXChenyi Xie
Chenyi Xie
ZNZiyu Ning
Ziyu Ning
TGTing Guo
Ting Guo
LYLisha Yao
Lisha Yao
XCXiaobo Chen
Xiaobo Chen
ZLZaiyi Liu
Zaiyi Liu
Adjuvant chemotherapy provides a limited survival benefit (<5%) for patients with stage II colorectal cancer (CRC) and is suggested for high-risk patients. Given the heterogeneity of stage II CRC, we aimed to develop a clinically explainable artificial intelligence (AI)-powered analyser to identify radiological phenotypes that would benefit from chemotherapy. Multimodal data from patients with CRC across six cohorts were collected, including 405 patients from the Guangdong Provincial People's Hospital for model development and 153 patients from the Yunnan Provincial Cancer Centre for validation. RNA sequencing data were used to identify the differentially expressed genes in the two radiological clusters. Histopathological patterns were evaluated to bridge the gap between the imaging and genetic information. Finally, we investigated the discovered morphological patterns of mouse models to observe imaging features. The survival benefit of chemotherapy varied significantly among the AI-powered radiological clusters [interaction hazard ratio (iHR) = 5.35, (95% CI: 1.98, 14.41), adjusted Pinteraction = 0.012]. Distinct biological pathways related to immune and stromal cell abundance were observed between the clusters. The observation only (OO)-preferable cluster exhibited higher necrosis, haemorrhage, and tortuous vessels, whereas the adjuvant chemotherapy (AC)-preferable cluster exhibited vessels with greater pericyte coverage, allowing for a more enriched infiltration of B, CD4+-T, and CD8+-T cells into the core tumoural areas. Further experiments confirmed that changes in vessel morphology led to alterations in predictive imaging features. The developed explainable AI-powered analyser effectively identified patients with stage II CRC with improved overall survival after receiving adjuvant chemotherapy, thereby contributing to the advancement of precision oncology. This work was funded by the National Science Fund of China (81925023, 82302299, and U22A2034), Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application (2022B1212010011), and High-level Hospital Construction Project (DFJHBF202105 and YKY-KF202204).

4 July 2025 in Science Advances
Verified
Journal Article
Open access
ZMZongchao Mo
Zongchao Mo
MYMei Yang
Mei Yang
ZZZhihan Zhu
Zhihan Zhu
MWMinghao Wang
Minghao Wang
HWHaoyu Wang
Haoyu Wang
ZLZaiyi Liu
Zaiyi Liu
Neoadjuvant therapy has been widely used in breast cancer, but treatment response varies among individuals. We conducted multiomic profiling on tumor samples from 149 Chinese patients with breast cancer across ER − HER2 + , ER + HER2 + , and ER − HER2 − subtypes, categorizing outcomes as pathologic complete response (pCR; n = 81) or residual disease (RD; n = 68). We identified distinct molecular features linked to pCR in each subtype: elevated cell proliferation in patients with ER − HER2 − pCR, higher CDKN2A methylation in patients with ER − HER2 − RD, increased KIT methylation in patients with ER − HER2 + RD, and MAP4K1 hypermethylation in patients with ER + HER2 + RD. These findings were subsequently validated in independent datasets. By integrating clinical and multiomic data, we developed MOPCR, a subtype-specific machine learning model that outperformed single-omic approaches in predicting treatment response. MOPCR demonstrated potential generalizability across cohorts and provided preliminary stratification of patient subgroups with higher pCR probability, offering valuable insights for precision cancer management.

1 June 2025 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
PLPenghao Lai
Penghao Lai
XCXiaobo Chen
Xiaobo Chen
WPWei Pei
Wei Pei
XHXia Huang
Xia Huang
ZFZhen Fang
Zhen Fang
HLHai Liao
Hai Liao
Background: Locally advanced nasopharyngeal carcinoma (LANPC) is a common malignant tumor of the nasopharynx, characterized by poor prognosis and a high susceptibility to recurrence and metastasis after surgery. The aim of this study was to establish and validate a radiomics model based on clinicopathological data and magnetic resonance imaging (MRI) information to predict progression-free survival (PFS) in LANPC patients, and to reveal the internal prediction process of the model through SHapley Additive exPlanation (SHAP) and image visualization techniques. Methods: A total of 1,098 patients with pathologically and clinically diagnosed LANPC were recruited from three hospitals {training, n=700 [70% from hospitals I (Guangxi Medical University Cancer Hospital) and II (Wuzhou Red Cross Hospital)]; internal validation, n=300 (remaining 30%); and external validation, n=98 [hospital III (The Second Affiliated Hospital of Guangxi Medical University)]}. Univariate Cox analysis and least absolute shrinkage and selection operator (LASSO) Cox regression were used to select radiomics features. A combined model integrating the radiomics score (radscore) and important clinicopathological factors was constructed using the eXtreme Gradient Boosting (XGBoost) algorithm. SHAP and image visualization techniques were used for interpretability analysis of prognostic models. Results: Optimal predictive performance was observed in the combined model, which integrated the radscore and important clinicopathological factors [induction chemotherapy (IC), Epstein-Barr virus (EBV)-DNA, and albumin], with Harrell concordance index (C-index) values of 0.762, 0.729, and 0.752 in the training, internal, and external validation cohorts, respectively. Ten radiomics features with the highest predictive contributions were identified using the SHAP algorithm. Two LANPC patients with similar clinicopathological stages but distinct risk levels were selected to visualize the top three radiomics features, revealing notable pixel-level visual differences in the largest layer of the tumor images. Kaplan-Meier survival analysis revealed prognostic differences between low- and high-risk groups, and the model’s performance was stable across subgroups (all log-rank P<0.05). Conclusions: The interpretable model was able to accurately predict the PFS in LANPC patients. SHAP and image visualization techniques provided quantitative contribution values and image-level radiomics information, which could provide valuable additional information for individualized prognostic evaluation and clinical decision-making for patients with LANPC.